Advertisement
Alexza Pharmaceuticals is a biopharmaceutical company focused on thedevelopment and commercialization of novel, proprietary products for thetreatment of acute and intermittent conditions. The Company's technology, theStaccato(R) system, vaporizes unformulated drug to form a condensation aerosolthat allows rapid systemic drug delivery through deep lung inhalation. Thedrug is quickly absorbed through the lungs into the bloodstream, providingspeed of therapeutic onset that is comparable to intravenous administration,but with greater ease, patient comfort and convenience. Alexza has sixproduct candidates in development; AZ-004 (Staccato loxapine) for thetreatment of acute agitation in schizophrenic and bipolar disorder patients,AZ-001 (Staccato prochlorperazine) for the acute treatment of migraineheadaches, AZ-104 (Staccato loxapine) for the acute treatment of migraineheadaches, AZ-002 (Staccato alprazolam) for the acute treatment of panicattacks associated with panic disorder, AZ-003 (Staccato fentanyl) for thetreatment of breakthrough pain in cancer and non-cancer patients, and AZ-007(Staccato zaleplon) for the treatment of insomnia. More information,including this and past press releases from Alexza is available online atwww.alexza.com.
Advertisement
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements thatinvolve significant risks and uncertainties. Any statement describing theCompany's expectations or beliefs is a forward-looking statement, as definedin the Private Securities Litigation Reform Act of 1995, and should beconsidered an at-risk statement. Such statements are subject to certain risksand uncertainties, particularly those inherent in the process of developingand commercializing drugs. The Company's forward-looking statements alsoinvolve assumptions that, if they prove incorrect, would cause its results todiffer materially from those expressed or implied by such forward-lookingstatements. These and other risks concerning Alexza's business are describedin additional detail in the Company's Annual Report on Form 10-K/A for theyear ended December 31, 2006, and the Company's other Periodic and CurrentReports filed with the Securities and Exchange Commission. Forward-lookingstatements contained in this announcement are made as of this date, and weundertake no obligation to publicly update any forward-looking statement,whether as a result of new information, future events or otherwise.
SOURCE Alexza Pharmaceuticals, Inc.
